Skip to content
Login
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Login
Log In
Account Settings
Login
Log In
Account Settings
Login
Sign Up
Real Clinics. Real Patients. Real Oncology.
Home
/
Tags
/
KEYNOTE-522
Home /
KEYNOTE-522
KEYNOTE-522
KEYNOTE-522
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
News & Insights
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Podcasts
No results were found
What are you looking for?
Search
Search
POPULAR SEARCHES
Adjuvant Therapy
Biomarker Testing
Bladder Cancer
Blood-Based Tests
